1.Development of epigenetic treatment in myelodysplastic syndromes
Journal of Leukemia & Lymphoma 2009;18(11):690-693
It have been known that many epigenetic alterations palyed an important role in development of myelodysplastic syndromes (MDS). In contrast to genetic alterations, epigenetic alterations could be in principle pharmacologically reversed. Application of epigenetic drugs can reactivate inactivated suppressor genes. Epigenetic drugs mainly include demethylating agents and histone deacylase (HDAC) inhibitors, which are available in treatment. 5-AZA and decitabine as DNA demethylation agents have been approved by FDAof treatment in intermediate or high risk MDS, especially those old patients who are resistant to chemotherapy.HDAC inhibitors such as valproic acid are mostly employed in phase I trial, probably effective in treating low risk MDS, but treatment schedules and curative effects still have to be evaluated. The combination of demethylation agents and HDAC inhibitors may result in synergistic activity, but its therapeutic effect seems not to be superior to monotherapy of demethylation agents in current clinical trials, and it still need new clinical trials containing more cases and rational treatment schedules to identify safety and effect of combination.
2.Expression of COX-2,Ki-67 and VEGF in bladder transitional epithelial cancers and their significance
Cancer Research and Clinic 2000;0(06):-
Objective To study COX-2 expression in bladder transitional cell carcinoma in order to explore the relationship between the immunohistochemical staining and biological behavior of bladder cancer. Methods The expression of COX-2,Ki-67,and VEGF was examined in 50 cases of bladder transitional cell carcinoma and 10 normal bladder mucosa by means of immunohistochemical technique.Results The expression of COX-2 in BTCCs was higher than that in normal bladder mucosa.The positive rate of COX-2 was 80% in BTCCs while it was not detected in normal bladder mucosa.COX-2 was highly positively related to the grade,stage and prognosis of tumors.The expression of COX-2 in poorly differentiated,invasive or re- curring BTCCs was higher than that in well differentiated superficial or nonrecurring ones.But there was not significant difference between the solitary tumour and multiple ones.There were positive correlation both be- tween COX-2 and Ki-67 and between COX-2 and VEGF.Conclusion The high expression of COX-2 may benefit increase in bladder cancer cell proliferative activity.VEGF expression in COX-2 positive tumor was significantly higher than that in COX-2 negative tumor.
4.Extranodal follicular dendritic cell sarcoma of neck region: report of a case.
Chinese Journal of Pathology 2012;41(6):410-411
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Carcinoma
;
metabolism
;
pathology
;
Cyclophosphamide
;
therapeutic use
;
Dendritic Cell Sarcoma, Follicular
;
drug therapy
;
metabolism
;
pathology
;
surgery
;
Diagnosis, Differential
;
Doxorubicin
;
therapeutic use
;
Head and Neck Neoplasms
;
drug therapy
;
metabolism
;
pathology
;
surgery
;
Humans
;
Lung Neoplasms
;
drug therapy
;
secondary
;
Male
;
Melanoma
;
metabolism
;
pathology
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Prednisone
;
therapeutic use
;
Receptors, Complement 3b
;
metabolism
;
Receptors, Complement 3d
;
metabolism
;
Vincristine
;
therapeutic use
5.Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis
Journal of China Pharmaceutical University 2020;51(4):425-432
Lymphatic metastasis is one of the main routes of tumor metastasis. The limitation of traditional medicine in the treatment of lymphatic tumor metastasis lies in the low concentration of the drug in lymphatic metastases resulting in poor efficacy. Nanocarrier-based drug delivery system plays an important role in enhancing drug targeting, improving drug bioavailability, and reducing side effects. This review introduces the composition and function of the lymphatic system as well as its role in tumor metastasis, enumerates the present therapeutic means and limitations of anti-tumor lymphatic metastasis, and focuses on the recent advances in the passive, active and antigen-presenting cell-mediated lymphatic targeted drug delivery systems in tumor metastasis are highlighted.
6.Comparison of sufentanil and fentanyl in total intravenous anesthesia for liver resection: A double blind randomized clinical trial
Feng XIAO ; Jin LI ; Junmei XU
Journal of Chinese Physician 2011;13(7):917-918,922
Objective To compare fentanyl and sufentanil in total intravenous anesthesia for liver resection. Methods 100 patients undergoing liver resection were randomly received either sufentanil (group S, n = 50) anesthesia or fentanyl (group C, n = 50). Hemodynamic variables, time to spontaneous eye opening and extubation were recorded. VAS-scale was used to assess postoperative pain. The incidence of nausea & vomiting, agitation and respiratory depression was recorded and compared. Results Patients in group S had a more stable hemodynamic variables, and the incidence of postoperative pain (VAS: group S 4. 2± 1.1, group C 6. 1 ± 1.2), agitation (group S 2 cases, group C 11 cases) and respiratory depression (group S 1 case, group C 5 cases)was lower. Conclusions Both sufentanil and fentanyl were safe and efficacious in total intravenous anesthesia for liver resection. Compared with fentanyl, Sufentanil had higher hemodynamic stability, and lower incidence of postoperative pain, respiratory depression and agitation.
7.Preparation and Quality Control of Thermo-sensitive Ornidazole Hydrogel
Xianling SHEN ; Chuanxin XU ; Feng XIAO
China Pharmacy 2001;0(07):-
OBJECTIVE: To prepare thermo-sensitive ornidazole hydrogel and establish its quality control method.METHODS: Thermo-sensitive ornidazole hydrogel was prepared with ornidazole as chief constituent using poloxamer 407 and poloxamer 188 as base.The content of ornidazole in the hydrogel was determined by ultraviolet spectrophotometry.RESULTS: The preparation was white or yellowish semisolid gel,and its test results were up to the related standard specified in Chinese Pharmacopeia(2005 Edition).The linear range of ornidazole was 3.98~43.77 mg?L-1(r=0.999 8),and its mean recovery was 98.52%(RSD=1.1%).CONCLUSION: The preparation is simple and feasible in preparation process,and the quality of the preparation is stable and controllable.
8.Percutaneous fenestration of intimal flap and endovascular stent placement for aortic dissection: 1 case report and reference review
Ke XU ; Liang XIAO ; Bo FENG
Chinese Journal of Radiology 2001;0(03):-
Objective To evaluate the safety and effect of percutaneous fenestration of intimal flap(FIF) and endovascular stent(ES) placement for aortic dissection. Methods Male patient, 54 years old. DeBakey Ⅲb aortic dissection, tear of intimal flap situated at the beginning of desconding aorta, developed to abdominal aorta and right iliac artery. The true lumen was 3 mm at narrowest locatation. Through femoral artery approach, percutaneous fenestration of intimal flap and ES placement are operated and four ES were placed. Results The blood flow of aortic true lumen and branches were resumed. The true lumen raised to 12 3 mm at the narrowest locatation. The clinical symptoms vanished. Conclusion Percutaneous fenestration and ES placement for aortic dissection feature little injure, high safety and effecacy. So, It is the first choice for certain aortic dissection.
10.Thinking of study on secondary development of major traditional Chinese medicine varieties based on system theory.
Xu-Dong CHENG ; Xiao-Bin JIA ; Liang FENG ; Jun JIANG
China Journal of Chinese Materia Medica 2013;38(24):4369-4374
The secondary development of traditional Chinese medicines (TCMs) is an important content of TCM modernization process, as well as an important path for developing new TCM drugs. Under the guidance of the system theory, in response to the lack of the overall guideline and practical methods for the secondary development of TCMs at present, we introduced the overall thought of the secondary development of major TCM varieties, as well as the roles and contents of clinical research, pharmacology and pharmaceutics in the process of the secondary development of major TCM varieties, so as to provide systematic strategies and methods for the development of major TCM varieties.
Biomedical Research
;
Drug Discovery
;
methods
;
Humans
;
Medicine, Chinese Traditional
;
methods
;
Pharmacology